Akari Therapeutics awards interim CFO 1,130 ADSs

Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.

Akari Therapeutics Plc reported that interim CFO Farag Kameel D. received a grant of 1,130 American Depositary Shares representing restricted stock units on July 16, 2026, at a reported price of $11.50 per share. According to the footnote, these ADSs represent RSUs, with each RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share, and the RSUs will vest in full on August 16, 2026. Following this award, the interim CFO directly owns 21,581 ADSs.

Insider Trade Summary

Grant/Award: 1,130 shares

Grant/Award 1 txn

Insider Farag Kameel D.

Role Interim CFO

Type	Security	Shares	Price	Value
Grant/Award	American Depositary Shares representing Ordinary Shares F1	1,130	$11.50	$13K

Holdings After Transaction: American Depositary Shares representing Ordinary Shares — 21,581 shares (Direct)

Footnotes (1)

1. F1. These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on August 16, 2026.

Key Figures

ADSs granted: 1,130 American Depositary Shares Grant value per ADS: $11.50 per American Depositary Share ADSs owned after transaction: 21,581 American Depositary Shares +3 more

6 metrics

ADSs granted 1,130 American Depositary Shares Grant/award to interim CFO on July 16, 2026

Grant value per ADS $11.50 per American Depositary Share Reported price for RSU-related ADS grant

ADSs owned after transaction 21,581 American Depositary Shares Direct holdings of interim CFO following grant

Ordinary shares per RSU 80,000 ordinary shares Each RSU represents right to receive this number of ordinary shares

Ordinary share par value $0.000000005 per ordinary share Par value of underlying ordinary shares

RSU vesting date August 16, 2026 RSUs underlying ADSs vest in full on this date

Key Terms

American Depositary Shares, restricted stock units, par value

3 terms

American Depositary Shares financial

"security titled American Depositary Shares representing Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted stock units financial

"These American Depositary Shares represent restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

par value financial

"ordinary shares with a par value of $0.000000005 per ordinary share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Akari Therapeutics (AKTX) disclose for interim CFO Farag Kameel D.?

Akari Therapeutics disclosed that interim CFO Farag Kameel D. received a grant of 1,130 American Depositary Shares on July 16, 2026. These ADSs represent restricted stock units (RSUs) with a reported price of $11.50 per share under an equity award.

How many Akari Therapeutics (AKTX) ADSs were awarded and at what reported price?

The interim CFO was awarded 1,130 American Depositary Shares of Akari Therapeutics at a reported value of $11.50 per share. These ADSs represent restricted stock units granted as part of compensation, as described in the Form 4 filing and its accompanying footnote.

When will the RSUs reported by Akari Therapeutics (AKTX) for its interim CFO vest?

The RSUs represented by the awarded ADSs will vest in full on August 16, 2026. Vesting means the interim CFO’s right to receive the underlying ordinary shares becomes non-forfeitable on that date, assuming the applicable award terms are satisfied.

What does each RSU granted by Akari Therapeutics (AKTX) to the interim CFO represent?

Each RSU granted to the interim CFO represents the right to receive 80,000 ordinary shares of Akari Therapeutics. Those ordinary shares have a stated par value of $0.000000005 per ordinary share, according to the footnote linked to the reported ADS award.

How many Akari Therapeutics (AKTX) ADSs does the interim CFO hold after this Form 4 transaction?

After the reported grant, the interim CFO directly holds 21,581 American Depositary Shares of Akari Therapeutics. This figure reflects total direct ownership of ADSs following the 1,130-share RSU-related award disclosed in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 06:30 PM Accepted by SEC EDGAR 08/05/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farag Kameel D.

(Last) (First) (Middle)

C/O AKARI THERAPEUTICS PLC

401 EAST JACKSON STREET, SUITE 3300

(Street)

TAMPA FLORIDA 33602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares representing Ordinary Shares	07/16/2026		A		1,130(1)	A	$11.5	21,581	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on August 16, 2026.

	/s/ Abizer Gaslightwala, as Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)